Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Forest Road Acquisition (FRX.U)
Upcoming IPO
Lixte Biotechnology Holdings (LIXT)
Seaport Global Acquisition (SGAMU)
Spartan Acquisition Corp. II (SPRQ.U)
AMMO (POWW)
Priced IPO
HF Enterprises (HFEN)
Vision Marine Technologies (VMAR)
Ozon Holdings Plc (OZON)
Sotera Health Company (SHC)
Maravai LifeSciences Holdings, Inc. (MRVI)
Telos Corporation (TLS)
NeoGames S.A (NGMS)
Olema Pharmaceuticals, Inc. (OLMA)
Yatsen Holding Limited (YSG)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
More companies

Repare Therapeutics Inc. (RPTX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a leading precision oncology company enabled by their proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Synthetic lethality, or SL, represents a clinically validated approach to drug development. They use their proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. SL arises when a deficiency in either of two genes is tolerated in cells, but simultaneous deficiencies in both genes cause cell death. Cancer cells that contain a mutation in one gene of a SL pair are susceptible to therapeutic intervention targeting the other gene pair. Using their SNIPRx platform, they are developing their pipeline of SL product candidates, including their lead product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. They anticipate filing an investigational new drug, or IND, application in the second quarter of 2020 and initiating an open-label Phase 1/2 clinical trial of RP-3500 in the third quarter of 2020.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Lloyd M. Segal Steve Forte
Employees Founded
64 2016

Contacts

Address: 7210 Frederick-Banting, Suite 100, Montréal, Québec, Canada H4S 2A1,

Telephone: (857) 412-7018

Web page: http://www.reparerx.com

IPO information

Expected Date 6/19/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $16.00-$18.00
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $647
Revenues (MM) $0
Net Income (Loss) (MM) $-34.98

Voting

What do you think will happen with the RPTX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 7.4
Shares Revised (MM) 11
Expected offer amount (MM) $190
Realized offer amount(MM) $220
Underwriters
Morgan Stanley/ Goldman Sachs/ Cowen/ Piper Sandler
CO-Managers
-

Sector: Healthcare

Tweets about $RPTX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats